Challenges in Cancer Immunotherapy Accessibility

Summary of Immunotherapy Developments and Challenges

1. Immunotherapy Advancements:

   • Immunotherapy has revolutionized cancer treatment, significantly improving survival rates for terminal cancers.
   • Example: Merck & Co’s Keytruda has shown efficacy in treating certain malignancies.

2. Ethical Concerns and Drug Pricing:

   • Keytruda pricing: A 100 mg vial costs ₹1.5 lakhs, leading to total treatment costs in tens of lakhs due to extended therapy durations.
   • Ethical issues arise from the high cost, leading to illicit activities involving hospital staff, pharmacists, and middlemen who redistribute used vials as genuine products at lower prices.

3. Regulatory and Supply Chain Issues:

   • The investigation highlights deficiencies in hospital waste disposal and inadequate tracking systems within the drug supply chain.
   • Lack of accountability in the pharmaceutical ecosystem.

4. Patent System and Access:

   • Merck holds a primary patent on pembrolizumab (Keytruda) until 2028, fortified by a "patent thicket" that complicates the introduction of cheaper alternatives.
   • India's patent laws historically aim to combat "evergreening," which is the strategy of extending patent protections to delay generic competition.

5. Biosimilars Development:

   • Indian pharmaceutical companies are developing biosimilars for Keytruda, which could reduce costs by up to 70%.
   • Biosimilars are derived from living cells, requiring advanced manufacturing, strict regulatory compliance, and lengthy development times (4-8 times longer than standard generics).

6. Judicial Rulings:

   • Indian courts have largely prioritized patient access in legal challenges against pharmaceutical giants.
   • However, legal processes can be lengthy, posing challenges for critically ill patients.

7. Immediate Recommendations:

   • India should improve regulatory oversight and expedite the approval process for biosimilars.
   • Shift from merely manufacturing affordable medicines to fostering domestic innovation in drug discovery.

8. Innovation in Healthcare:

   • India’s success with CAR-T therapy exemplifies the potential for homegrown solutions to reduce costs and increase access.
   • Key factors for scaling this model include:
     • Sustained investment in research and development (R&D).
     • Enhanced collaboration between academia and industry.
     • Efficient regulations that maintain safety without sacrificing speed.
     • Financing mechanisms that accommodate risks inherent in biotechnology.

9. Urgency of Action:

   • With India having the world’s third-largest cancer burden, it is essential to initiate discussions and actions towards drug discovery and innovation immediately.

Conclusion:

• To advance patient access to effective cancer treatments and support the development of biosimilars and innovative therapies, India must address regulatory frameworks and strengthen its pharmaceutical research infrastructure. The integration of advanced R&D, collaboration, and streamlined approvals will be crucial for achieving these goals.